

09/623828

1/26




FIGURE 1A

09/623828

2/26





FIGURE 1B


3/26



**POPULATION 2**  
 OF NUCLEIC ACIDS  
 CHARACTERISTIC OF CONDITION  
 (A) SPLICING PATTERNS WITH  
 RESPECT TO CONDITION (B)  
 SPLICING PATTERNS


**POPULATION 1**  
 OF NUCLEIC ACIDS  
 CHARACTERISTIC OF CONDITION  
 (B) SPLICING PATTERNS WITH  
 RESPECT TO CONDITION(A)  
 SPLICING PATTERNS

FIGURE 1C

**FIGURE 1D**

09/623828

5/26




**FIGURE 2**

09/623828

6/26


path. RNA/normal cDNA hybrids




non spliced sequences after RNase H digestion



desired sequence which is 5'- and 3'-  
labelled by two oligonucléotides



PCR-amplified fragment




cloning and sequencing

**FIGURE 3**

09/623828

7/26



8/26




FIGURE 5

09/623828

9/26


A

B


Conditions A and B  
of cDNA




mRNA




1st strands of cDNA  
in conditions A and B




2nd strand of cDNA in A



Hybridization of the 2 strands of A  
with the 1st strand of B




Digestion with Sau3AI



Separation of loops engaged into duplex




Addition of linkers to the sites Sau3AI



PCR Amplification and cloning


**FIGURE 6A**

10/26

**FIGURE 6B**

09/623828

11/26





**FIGURE 7**

09/623828

12/26

Figure 8



09/623828

13/26




Figure 9

09/623828

14/26

1 2 3 4 5 6 7 8 9 10 11 12 13





Figure 10

09/623828

15/26

A)

1 2 3



B)

1 2 3 4 5 6 7 8 9 10 11 12




Figure 11

16/26





Figure 12


09/623828

17/26

A \_\_\_\_\_ B  
|  
Construction of qualitative differential libraries corresponding to different dots of toxicity abacus-like charts




Hybridization with probes derived from the model treated by different products



**FIGURE 13**

09/623828


18/26



**FIGURE 14**

09/623828

19/26



responder-derived biopsy samples



unresponder-derived biopsy samples



**FIGURE 15**

09/623828

20/26




Figure 16

09/623828

21/26

Peptidic Sequence of ΔSHC (SEQ ID NO: 9)

1

MNKLSGGGGR RTRVEGGQLG GEEWTRHGSF VNKPTRGWLH PNDKVMGPGV  
SYLVRYMGCV EVLQSMRALD FNTRTQVTRE AISLVCEAVP GAKGATRRK  
PCSRPLSSIL GRSNLKFAGM PITLTGSTSS LNLMAADCKQ IIANHHMQSI  
SFASGGDPDT AEYVAYVAKD PVNQRACHIL ECPEGLAQDV ISTIGQAFEL  
RFKQYLRNPP KLVTPHDRMA GFDGSAWDEE EEEPPDHQYY NDFPGKEPPL  
GGVVDMRLRE GAAPGAARPT APNAQTPSHL GATLPVGQPV GGDPEVRKQM  
PPPPPCCPGRE LFDDPSYVNV QNLDKARQAV GGAGPPNPAI NGSAPRDLFD  
MKPFEDALRV PPPPQSVSMA EQLRGEPWFH GKLSRREAEA LLQLNGDFLV  
RTKDHRFESV SHLISYHMDN HLPIIISAGSE LCLQQPVERKL

441

Nucleic Sequence of ΔSHC (SEQ ID NO: 10)

atgaacaaggc	tgagtggagg	cggcgccgcgc	aggactcggt	tggaaggggg	50
ccagcttggg	ggcgaggagt	ggacccgcca	cgggagcttt	gtcaataaggc	100
ccacgcgggg	ctggctgcat	cccaacgaca	aagtcatggg	accgggggtt	150
tcctacttgg	ttcggtacat	gggttgtgtg	gaggtccctcc	agtcaatgcg	200
tgcctggac	ttcaaacaccc	ggactcaggt	caccaggag	gccatcagtc	250
tggtgtgtga	ggctgtgccg	ggtgctaagg	gggcgacaag	gaggagaaag	300
ccctgttagcc	gcccgcctcag	ctctatcctg	gggaggagta	acctgaaatt	350
tgctggaatg	ccaatcactc	tcaccgtctc	caccagcagc	ctcaacactca	400
tggccgcaga	ctgcaaacag	atcatcgcca	accaccat	gcaatctatc	450
tcatttgcac	ccggcgggga	tccggacaca	gccgagtatg	tgccttatgt	500
tgccaaagac	cctgtgaatc	agagagcctg	ccacattctg	gagtgtcccg	550
aagggtttgc	ccaggatgtc	atcagcacca	ttggccaggc	cttcgagttg	600
cgcattcaaacc	aatacctcag	gaaccaccc	aaactggtca	cccctcatga	650
caggatggct	ggctttgatg	gctcagcatg	ggatgaggag	gaggaagagc	700
cacctgacca	tcagttactat	aatgacttcc	cggggaaagga	accccccttg	750
gggggggtgg	tagacatgag	gcttcggaa	ggagccgctc	caggggctgc	800
tgcacccact	gcacccaatg	cccagacccc	cagccacttg	ggagctacat	850
tgcctgttagg	acagcctgtt	gggggagatc	cagaagtccg	caaacagatg	900

**FIGURE 17A**

09/623828

22/26

ccacctccac caccctgtcc aggcagagag cttttgatg atccccta 950  
tgtcaacgtc cagaacctag acaaggcccg gcaagcagtg ggtggtgctg 1000  
ggcccccaa tcctgctatc aatggcagtg cacccggga cctgttgac 1050  
atgaagccct tcgaagatgc tcttcgggtg cctccacctc cccagtcggt 1100  
gtccatggct gagcagctcc gaggggagcc ctggttccat gggaaagctga 1150  
gccggcggga ggctgaggca ctgctgcagc tcaatggga cttcttggtt 1200  
cgactaagg atcaccgctt tgaaagtgtc agtcacctta tcagctacca 1250  
catggacaat cactgcccc tcatctctgc gggcagcga ctgtgtctac 1300  
agcaacctgt ggagcggaaa ctgtga 1326


**FIGURE 17B**

09/623828


23/26

Trypan Blue

HepG2 / Ethanol




MTT Test



**FIGURE 18A**

ELISA Test - Fragmentation of DNA




09/623828

24/26

## HepG2 / Camptothecin

Trypan Blue



MTT Test





FIGURE 18B


ELISA Test - Fragmentation of DNA




09/623828

25/26

HepG2 / PMA  
Trypan Blue




Test MTT



ELISA Test - Fragmentation of DNA

FIGURE 18C



09/623828

26/26

Figure 19

